Martin Sjostrom, MD, PhD
Assistant Professor
Urology
School of Medicine

Publications (18)

Top publication keywords:
Gene Expression Regulation, NeoplasticNeoplastic Cells, CirculatingAndrogen Receptor AntagonistsGenomic Structural VariationProstatic Neoplasms, Castration-ResistantDrug Resistance, NeoplasmHepatocyte Nuclear Factor 3-alphaChromatinDisease ProgressionCell LineageReceptors, AndrogenCell PlasticityProstatic NeoplasmsEpigenesis, GeneticNeoplasm Metastasis

• Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Tolmeijer SH, Kwan EM, Gafita A, Hamid AA, Keerthikumar S, Ayati N, Bressel M, Joshua AM, Emmett L, Crumbaker M, Ng SWS, Donnellan G, Anton A, Spain L, Horvath LG, Chan J, Buteau JP, van Mourik A, …
• Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.
  Genome biology 2026 Moreno-Rodriguez T, Zhang M, Lundberg A, Shrestha R, Sjöström M, Pasam A, Chan J, Devereux L, Foye A, Zhu X, Weinstein AS, Trigos AS, Wyatt AW, Alumkal JJ, Small EJ, Aggarwal R, Dehm SM, Bootsma ML, …
• Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.
  Nature genetics 2025 Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sjöström M, Feng S, Anderson JA, Han W, Chesner LN, Shin HJ, Farsh T, Suarez HJ, Nath S, Chou J, Das R, Egusa EA, Calvert M, Kishishita A, Barpanda A, Zhu…
• Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity.
  Nature communications 2025 Liu T, Zhang M, Farsh T, Li H, Kishishita A, Barpanda A, Leung SG, Zhu J, Jung H, Hua JT, Zhu X, Kim AB, Goo YA, Son M, Kim J, Subramanian A, Sjöström M, Fuh KC, Chapman JS, Carnevale J, Gilbert LA, …
• PROX1 is an early driver of lineage plasticity in prostate cancer.
  The Journal of clinical investigation 2025 Duan Z, Shi M, Kumaraswamy A, Lin D, Khokhani D, Wang Y, Zhang C, Flores D, Rodansky E, Swaim OA, Storck WK, Beck HN, Patel RA, Sayar E, Hanratty BP, Xue H, Dong X, Maylin ZR, Wan R, Quigley DA, …

Show all (13 more) Hide

• Identifying prognostic targets in metastatic prostate cancer beyond AR.
  FEBS open bio 2025 Feng E, Feng E, Berg T, Nguyen IS, Nguyen LG, Chen W, Zhang M, Quigley D, Sharifi M, Li H, Coleman I, Nelson PS, Sjöström M, Zhao SG
• Racial variation in the advanced prostate cancer genome.
  Prostate cancer and prostatic diseases 2025 Feng EM, Vo-Phamhi J, Subramanian AN, Dias M, Foye A, Vinson J, Hong JC, Freedland SJ, Alumkal JJ, Beltran H, Morrissey C, Nelson PS, Chinnaiyan AM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao …
• Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.
  Cancer discovery 2025 Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, Das R, Shenoy T, Sjöström M, Zhao F, Hu YM, Linder S, Chen WS, Hawkins RM, Shrestha R, Zhu X, Foye A, Li H, Kim LM, Bhalla M, O'…
• Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
  Journal of the National Cancer Institute 2025 Karlsson P, Fyles A, Chang SL, Arrick B, Baehner FL, Malmström P, Fernö M, Holmberg E, Sjöström M, Liu FF, Cameron DA, Williams LJ, Bartlett JMS, Dunlop J, Caldwell J, Loane JF, Mallon E, Piper T, …
• Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer.
  Molecular oncology 2025 Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzer GC, Shang TA, Subramanian A, Bjartell A, Josefsson A, Wikström P, Feng…
• High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.
  Cancer discovery 2025 Sharifi MN, Sperger JM, Taylor AK, Tippins KE, Reese SR, Carreno V, Kaufmann KR, Chang AH, Nunamaker LA, Linebarger C, Mora-Rodriguez L, Schehr JL, Krause HM, Helzer KT, Bootsma ML, Blitzer GC, …
• Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate.
  Nature communications 2024 Chen X, Augello MA, Liu D, Lin K, Hakansson A, Sjöström M, Khani F, Deonarine LD, Liu Y, Travascio-Green J, Wu J, Chan UI, Owiredu J, Loda M, Feng FY, Robinson BD, Davicioni E, Sboner A, Barbieri CE
• A phenocopy signature of TP53 loss predicts response to chemotherapy.
  NPJ precision oncology 2024 Bakhtiar H, Sharifi MN, Helzer KT, Shi Y, Bootsma ML, Shang TA, Chrostek MR, Berg TJ, Carson Callahan S, Carreno V, Blitzer GC, West MT, O'Regan RM, Wisinski KB, Sjöström M, Zhao SG
• An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression.
  Cancer research 2024 Shrestha R, Chesner LN, Zhang M, Zhou S, Foye A, Lundberg A, Weinstein AS, Sjöström M, Zhu X, Moreno-Rodriguez T, Li H, SU2C/PCF West Coast Prostate Cancer Dream Team, Alumkal JJ, Aggarwal R, Small EJ…
• Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.
  The Journal of clinical investigation 2024 Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, Sjöström M, Shrestha R, Kneppers J, Severson T, Zhang M, Lundberg A, Moreno Rodriguez T, Weinstein AS, Foye A, Mehra N, Aggarwal RR, Bergman AM, Small EJ, …
• ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
  Cancer discovery 2024 Xu Y, Yang Y, Wang Z, Sjöström M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, Xu Q, Tirado CR, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y,…
• Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.
  Nature genetics 2024 Zhao SG, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, Pan C, Arlidge C, Hawley JR, Foye A, Weinstein AS, Sjöström M, Zhang M, Li H, Chesner LN, Rydzewski NR, Helzer KT, Shi Y, West …
• Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.
  Nature cell biology 2024 Zhang M, Sjöström M, Cui X, Foye A, Farh K, Shrestha R, Lundberg A, Dang HX, Li H, Febbo PG, Aggarwal R, Alumkal JJ, Small EJ, SU2C/PCF West Coast Prostate Cancer Dream Team, Maher CA, Feng FY, …